Last reviewed · How we verify
QUINIDINE
Dextromethorphan acts as a sigma-1 receptor agonist and NMDA receptor antagonist, while quinidine increases its plasma levels by inhibiting CYP2D6.
At a glance
| Generic name | QUINIDINE |
|---|---|
| Target | sigma-1 receptor, NMDA receptor, CYP2D6 |
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1950 |
Mechanism of action
Dextromethorphan works by binding to sigma-1 receptors and acting as an uncompetitive antagonist at NMDA receptors. Quinidine enhances its effect by preventing its breakdown through inhibition of the CYP2D6 enzyme.
Approved indications
Common side effects
- Diarrhea
- Dizziness
- Cough
- Vomiting
- Asthenia
- Peripheral edema
- Urinary tract infection
- Influenza
- Increased gamma-glutamyltransferase
- Flatulence
Key clinical trials
- A Trial to Test the Effects of Other Drugs on SEP-380135 in Healthy Men and Women (PHASE1)
- A Study of Imlunestrant (LY3484356) in Female Healthy Participants (PHASE1)
- Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury (PHASE2)
- Long Term, Extension Study of the Safety and Efficacy of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type (PHASE3)
- A Study to Assess the Effect of Voriconazole and Quinidine on the Pharmacokinetics of a Single Dose of Repotrectinib in Healthy Participants (PHASE1)
- A Study to Investigate the Effect of Food on Balcinrenone/Dapagliflozin Pharmacokinetics in Fed and Fasted State and Pharmacokinetics of Balcinrenone When Dosed With a P-gp Inhibitor in Healthy Participants. (PHASE1)
- A Study to Investigate the Pharmacokinetics of AZD2389 in Healthy Participants When Administered Alone and in Combination With Quinidine (PHASE1)
- A Drug-Drug Interaction Study to Evaluate the Effects of Itraconazole, Carbamazepine, Quinidine and Fluconazole on the Pharmacokinetics and Safety of EDP-323. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- QUINIDINE CI brief — competitive landscape report
- QUINIDINE updates RSS · CI watch RSS